Table 1.
Malignant neoplasms of 624 liver lesions diagnosed by FNB
| Cytologic diagnosis | Origin/site/type | Number of cases | Total number |
|---|---|---|---|
| Metastatic adenocarcinoma | 317 (50.8%) | ||
| GI tract | 143 (45.1%) | ||
| Pancreatobiliary | 74 (23.3%) | ||
| Breast | 44 (13.9%) | ||
| Lung | 24 (7.6%) | ||
| GYN tract | 12 (3.8%) | ||
| Kidney | 12 (3.8%) | ||
| Prostate | 5 (1.6%) | ||
| Thyroid | 1 (0.3%) | ||
| Adrenal | 2 (0.6%) | ||
| Hepatocellular carcinomaa | 97 (15.5%) | ||
| Cholangiocarcinomaa | 73 (11.7%) | ||
| Neuroendocrine neoplasm | 58 (9.3%) | ||
| Well-differentiated NETs | 16 (27.6%) | ||
| Poorly-differentiated NECs | 42 (72.4%) | ||
| Squamous cell Carcinoma | 24 (3.8%) | ||
| Lymphoma | 17 (2.7%) | ||
| DLBCL | 11 (64.7%) | ||
| Hodgkin lymphoma | 3 (17.6%) | ||
| SLL/CLL | 1 (5.9%) | ||
| Follicular lymphoma | 1 (5.9%) | ||
| Multiple myeloma | 1 (5.9%) | ||
| Sarcoma | 11 (1.8%) | ||
| Leiomyosarcoma | 3 (27.2%) | ||
| EBV-associated leiomyosarcomaa | 1 (9.1%) | ||
| Undifferentiated pleomorphic sarcoma | 2 (18.2%) | ||
| Embryonal sarcomaa | 1 (9.1%) | ||
| Malignant SFT | 1 (9.1%) | ||
| Myxoid liposarcoma | 1 (9.1%) | ||
| GIST | 2 (18.2%) | ||
| Melanoma | 4 (0.6%) | ||
| Combined HCC-CCa | 3 (0.5%) | ||
| Urothelial carcinoma | 3 (0.5%) | ||
| Thymic carcinoma | 2 (0.3%) | ||
| Hepatoblastomaa | 1 (0.2%) | ||
| Paragnaglioma | 1 (0.2%) | ||
| Mesothelioma | 1 (0.2%) | ||
| CUP | 12 (1.9%) | ||
| Total | 624 (100%) |
aIndicate primary liver malignant lesions
GI Gastrointestinal, GYN Gynecology, NETs Neuroendocrine tumors, NECs Neuroendocrine carcinomas, DLBCL Diffuse large B cell lymphoma, SLL/CLL Small lymphocytic lymphoma/Chronic lymphocytic leukemia, EBV Epstein-Barr virus, SFT Solitary fibrous tumor, GIST Gastrointestinal stroma tumor, HCC-CC Hepatocellular-cholangiocarcinoma, CUP Carcinoma of unknown primary